 This is a 1:1 randomized double-blind Placebo-controlled moncenter Phase IV study to investigate whether a successful interferon-free treatment of HCV-infection with ombitasvirparitaprevirritonavir OBVPTVr in combination with dasabuvir DSV improves the patients attention ability as compared to placebo as measured with the Att Test Sum Score change from baseline to week 12. A total of 30 patients with non-cirrhotic genotype 1b HCV infection will be randomly assigned to receive 12 weeks verum followed by 12 weeks Placebo arm A versus 12 weeks Placebo followed by 12 weeks verum arm B. Patients will be followed up for 48 weeks. 